1. Home
  2. FGEN vs IRD Comparison

FGEN vs IRD Comparison

Compare FGEN & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • IRD
  • Stock Information
  • Founded
  • FGEN 1993
  • IRD 2018
  • Country
  • FGEN United States
  • IRD United States
  • Employees
  • FGEN N/A
  • IRD N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • FGEN Health Care
  • IRD
  • Exchange
  • FGEN Nasdaq
  • IRD NYSE
  • Market Cap
  • FGEN 34.5M
  • IRD 36.0M
  • IPO Year
  • FGEN 2014
  • IRD N/A
  • Fundamental
  • Price
  • FGEN $0.55
  • IRD $1.13
  • Analyst Decision
  • FGEN
  • IRD Strong Buy
  • Analyst Count
  • FGEN 0
  • IRD 1
  • Target Price
  • FGEN N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • FGEN 753.5K
  • IRD 150.5K
  • Earning Date
  • FGEN 02-24-2025
  • IRD 02-24-2025
  • Dividend Yield
  • FGEN N/A
  • IRD N/A
  • EPS Growth
  • FGEN N/A
  • IRD N/A
  • EPS
  • FGEN N/A
  • IRD N/A
  • Revenue
  • FGEN $180,015,000.00
  • IRD $8,381,000.00
  • Revenue This Year
  • FGEN $21.91
  • IRD N/A
  • Revenue Next Year
  • FGEN N/A
  • IRD $29.37
  • P/E Ratio
  • FGEN N/A
  • IRD N/A
  • Revenue Growth
  • FGEN 16.15
  • IRD N/A
  • 52 Week Low
  • FGEN $0.18
  • IRD $0.81
  • 52 Week High
  • FGEN $2.80
  • IRD $2.71
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 58.51
  • IRD N/A
  • Support Level
  • FGEN $0.46
  • IRD N/A
  • Resistance Level
  • FGEN $0.51
  • IRD N/A
  • Average True Range (ATR)
  • FGEN 0.04
  • IRD 0.00
  • MACD
  • FGEN 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • FGEN 72.57
  • IRD 0.00

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: